Best of ASCO - 2014 Annual Meeting

 

Welcome

Value/Cost of Care

Health Services Research, Clinical Informatics, and Quality of Care

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A population-based comparison of cancer and non-cancer related healthcare costs.

Davis Sam

e18900

A proportional comparison of cancer burden and patient advocacy organization (PAO) funding by histology demonstrates many underfunded histologies.

Suneel Deepak Kamath

6606

A survey of perceptions of healthcare workers on the cost and safety of oral oncolytic agents in practice.

Madeline Tompkinson

e18926

A value framework analysis of the Canadian Cancer Trials Group.

Joseph Del Paggio

6614

Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).

Scott David Ramsey

6512

Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?

Andrea Phillips Sitlinger

6620

Clinical and economic burden of serious adverse events (SAEs) in an early phase trials unit.

Anna Rachel Minchom

e18890

Considering cost and value with patients in clinic.

Jeffrey M. Peppercorn

e18905

Cost avoidance through the medically integrated dispensary for oral chemotherapy: Utilizing the NCODA cost avoidance and waste tracker.

Joshua Nubla

e18916

Cost comparison of surveillance for HPV-positive versus HPV-negative oropharyngeal cancer.

Eugenie Du

e18908

Cost effectiveness (CE) of blinatumomab (BLIN) vs inotuzumab ozogamicin (INO) in adult patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) with no more than one prior salvage therapy (S0/S1) from a US payer perspective.

Thomas E. Delea

e18895

Cost of oncology drugs in the Middle-Eastern country of Lebanon: An update (2014-2016).

Ibrahim R. Bou-Orm

e18917

Cost saving analysis of reduced-dose versus standard-dose bevacizumab in recurrent glioblastoma.

Jack Patrick Gleeson

e18910

Cost variance analysis in treatment of advanced non-small cell lung cancer.

Prachi Kalamkar

e18929

Cost-effectiveness analysis (CEA) of current immunotherapy: World comparison results.

Fernanda Oliveira

e18930

Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).

Chethan Ramamurthy

6514

Cost-effectiveness analysis of aprepitant in Japanese patients who received high-dose cisplatin.

Ikuto Tsukiyama

e18924

Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.

Scott F. Huntington

6609

Cost-effectiveness analysis of cytoreductive surgery and HIPEC compared to systemic chemotherapy in isolated peritoneal carcinomatosis from metastatic colorectal cancer.

Trevor D Hamilton

e18897

Cost-effectiveness analysis of nivolumab and apatinib in third-line gastric cancer therapy.

Jiajia Yuan

e18931

Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.

Preethi John

e18887

Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia.

Reith Sarkar

6610

Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients.

Lotte Maria Gertruda Steuten

6513

Cost-related changes in medication use among cancer survivors by socioeconomic status.

Jingxuan Zhao

e18920

Design and implementation of a novel value framework for oncology clinical pathway decision-making: Chemotherapy comparative index and scale.

Edward C. Li

e18925

Dissemination of information on neutropenic diet (ND) by top U.S. cancer centers: In line with evidence?

Dhruvika Mukhija

e18940

Downstream revenue attributable to lung cancer screening program serving a minority predominant population.

Arden Plumb

e18909

Duration of physician-industry relationships and prescribing changes in oncology.

Aaron Philip Mitchell

6607

End of life spending among cancer patients in an ACO vs. non-ACO.

Miranda Lam

6511

Expression of uncertainty in oncology articles with marginally significant results.

Sam Rubinstein

e18907

Febrile neutropenia-related care and associated costs in elderly cancer patients.

Shuling Li

e18933

Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.

Di Maria Jiang

6619

Healthcare resource use and expenditures among patients with Merkel cell carcinoma by level of comorbidity.

Mairead Kearney

e18932

Healthcare resource utilization (HRU) and costs associated with renal impairment (RI) among treated multiple myeloma (MM) patients.

Rohan Medhekar

e18922

Hospitalization costs among chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI).

Krishnan Ramaswamy

e18893

Immunotherapy (IO) versus non-IO for oncology drugs: Comparing survival benefits (SB) using restricted mean survival time.

Amanda Putri Rahmadian

6617

Impact of a fully integrated specialty pharmacy on patients’ out-of-pocket cost for oral therapies in a hematology clinic.

Jeremiah Moore

e18928

Impact of Canadian Cancer Trials Group (CCTG) phase III trials (P3Ts).

Patricia A. Tang

e18901

Impact of clinical characteristics and unmet need on oncology combination pricing.

Priya Madhavan

e18941

Impact of competitive landscape and ownership dynamics on oncology combination pricing.

Priya Madhavan

e18942

Increased length of stay and cost of hospitalization in patients receiving inpatient radiation therapy.

Shirin Attarian

e18936

Indication specific pricing for targeted therapies: Using bevacizumab as an example.

John P. Geisler

e18939

Integrating comprehensive point of care and preemptive pharmacogenomic testing for patients with gastrointestinal malignancies.

Caren Hughes

e18935

Lung cancer screening findings in academic versus community imaging centers.

Katherine Janssen

e18915

Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.

Pedro Nazareth Aguiar

6615

Number needed to treat (NNT) and cost of preventing an event (COPE) of PD-1/PD-L1 antibodies for previously treated advanced non-small cell lung cancer (NSCLC) patients in Brazil.

Fernanda Oliveira

e18899

Oncology drug approval: Questioning efficacy evidence.

Amina B. Taleb

e18888

Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphoma—Results of caregiver work limitations questionnaire (CG WLQ).

Susan K. Parsons

e18927

Promoting high value care by de-adopting the neutropenic diet.

Arjun Gupta

e18918

Quantitating incremental value in oncology.

Jacob D. Bitran

e18896

Resource consumption and financial burden of cancer patients.

Nicholas George Zaorsky

e18913

Risk and cost of chemotherapy-induced thrombocytopenia (CIT) in US clinical practice.

Derek Weycker

e18911

The benefit of cost-sharing subsidies in the treatment of chronic myeloid leukemia (CML) after price surging of tyrosine kinase inhibitors (TKIs).

Erlene Kuizon Seymour

e18889

The cost and cost-effectiveness of a pediatric cancer unit (PCU) in the context of universal health coverage (UHC): A report from the Childhood Cancer 2030 Network.

Fernando Sanchez-Zubieta

e18891

The economic effectiveness of fidaxomicin over vancomycin in treating clostridium difficile infection in cancer patients: A systematic review.

Omar Khaled Mahmoud Abughanimeh

e18923

The effect of supervised, individualized exercise on cost savings during cancer treatment.

Karen Y Wonders

6605

The estimated financial impact of diagnostic accuracy on melanoma diagnosis in 2018.

Kelly Nelson

e18903

The financial impact of hypofractionated radiation for prostate cancer.

Assaf Moore

6613

The potential cost-effectiveness of first-line immunotherapy + chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).

Joshua A. Roth

6612

Trajectories of medical care cost by service type for recurrent and de novo advanced cancer patients.

Matthew P. Banegas

6611

Trends of hospitalizations with invasive fungal infections in patients with acute leukemia and hematopoietic stem cell from 2005-2014 in the United States.

Sukriti Kamboj

6618

Trends of new cancer drug approvals from the perspective of a publicly funded healthcare system: Analyses of the pan-Canadian Oncology Drug Review (pCODR) recommendations.

Saroj Niraula

6516

Universal health insurance does not protect from financial burden: A survey of Israeli cancer patients.

Barliz Waissengrin

e18898

Use of abiraterone and enzalutamide beyond PSA progression in metastatic prostate cancer.

Daniel Jacob Becker

e18921

Use of immunotherapy (IO) supplied free of charge to cancer patients.

Rajiv Agarwal

e18914

Utilization of imaging during staging and surveillance of localized colon cancer in a large insured population.

Urshila Durani

6616

What role does the patient perspective play in determining access to innovative therapies?

Clare Frances Jones

6608

Why do industry and payers disagree on the value of novel pharmaceuticals?

Henry Jacob Conter

e18886